Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies

BACKGROUND: Interleukin (IL)‐31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus. Nemolizumab, a humanized monoclonal antibody against IL‐31 receptor A, reduced pruritus in patients with AD after a 16‐week admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305216/
https://www.ncbi.nlm.nih.gov/pubmed/34726262
http://dx.doi.org/10.1111/bjd.20873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305216/
https://www.ncbi.nlm.nih.gov/pubmed/34726262
http://dx.doi.org/10.1111/bjd.20873

Ejemplares similares